MIRA-55
Anxiety & Cognitive Decline (e.g., early-stage dementia)
Key Facts
About MIRA Pharmaceuticals
MIRA Pharmaceuticals is a clinical-stage company developing novel oral analogs of ketamine (Ketamir-2) and marijuana (MIRA-55) for neurologic and neuropsychiatric disorders. Its key achievement is securing a preliminary DEA review stating its lead candidates are not considered controlled substances, which could significantly reduce regulatory and commercial hurdles. The strategy focuses on molecular modification to enhance oral bioavailability and therapeutic windows for large, underserved markets like treatment-resistant depression and neuropathic pain. With a valuation of ~$40M and its programs in preclinical/Phase 1 stages, MIRA represents a high-risk, high-potential investment in next-generation neuroscience therapeutics.
View full company profile